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Conclusions: Routine screening is not warranted as
no hVISA isolates were detected. Some strains had a
Macro E-test MIC of 6.0g/ml for both glycopeptides.
This suggests that periodic screening of S. aureus isolates
from BSI may be useful to check for the occurrence of
hVISA.
doi:10.1016/j.ijid.2008.05.717
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Objectives: S. pneumoniae (SPN) continues to be recog-
nized as a signiﬁcant respiratory and bacteremic pathogen.
Resistance to both oral and parenteral antibiotics used to
treat SPN infection is evolving and newer antibiotics are
needed with anti-SPN activity. This report documents the
activity of tigecycline and comparators against 5501 SPN
collected globally since 2004.
Methods: Between 2004—2007, 387 hospital sites in 48
countries collected 5501 SPN deemed clinically signiﬁcant
from a variety of sources. MICs were determined at each
site using supplied brothmicrodilution panels and MIC results
interpreted by CLSI standards at each site.
Results: The % SPN inhibited at each MIC are shown
below:
Conclusions: Tigecycline demonstrated excellent in vitro
activity against SPN with 100% of isolates inhibited at
≤0.5mcg/ml. Globally, only 61.5% of SPN were suscepti-
ble to penicillin, while 0.2% were resistant to levoﬂoxacin.
Continued surveillance of resistance in SPN to new and
established antimicrobials is warranted.
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Objectives: Tigecycline, a new glycylcycline is an ana-
logue of tetracycline that demonstrates activity against
bacterial strains carrying tetracycline (minocycline) resis-
tance mechanisms. This report documents the activity of TIG
against minocycline resistant isolates collected worldwide,
2004—2007, as part of the Tigecycline Evaluation Surveil-
lance Trial (TEST) study.
Methods: Between 2004 and 2007, 387 hospital sites in
48 countries collected signiﬁcant pathogens associated with
8 specimen types, were identiﬁed to species level and MICs
performed for each strain to a supplied panel of antibiotics
and interpreted according to CLSI guidelines.
Results: The table below illustrates the activity of tige-
cycline to minocycline resistant pathogens.
Conclusions: Tigecycline MIC90s were ≤0.5mcg/ml for
minocycline resistant gram-positive pathogens such as Ente-
rococcus and S. aureus (including MRSA) and ≤8mcg/ml
for minocycline resistant gram-negative pathogens such
as Enterobacteriaceae, including ESBL producers. Tigecy-
cline demonstrated minimal activity against P. aeruginosa.
Tigecycline demonstrates enhanced activity to many
minocycline resistant pathogens.
doi:10.1016/j.ijid.2008.05.719
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Background: Worldwide S. aureus are increasingly dis-
playing resistance to multiple drug classes. Therapeutic
options to multi-drug resistant (MDR) S. aureus phenotypes
are limited. Tigecycline, a new glycylcycline offers the
potential of enhanced activity against MDR S. aureus. The
tigecycline evaluation surveillance trial (T.E.S.T.) evaluated
the activity of tigecycline and comparators to MDR S. aureus
isolated worldwide.
Methods: 335 hospital sites in 47 countries between 2004
and 2007 collected 7,557 clinically signiﬁcant S. aureus.
MICs were determined using broth microdilution panels and
results interpreted as speciﬁed by CLSI at each site. S.
aureus strains were categorized into groups according to the
number of drug classes to which they were resistant (MDR
groups 0 to 4).
Results: MIC90 of tigecycline and comparators for MDR
groups 0 to 4 are shown in the table.
Conclusions: Tigecycline in comparison to 10 relevant
comparators exhibited the lowest MIC90 against S. aureus
isolated worldwide irrespective of MDR phenotype and mul-
tiple drug class resistance.
doi:10.1016/j.ijid.2008.05.720
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Background: Daptomycin is a cyclic lipopeptide with
potent bactericidal activity against Gram-positive organ-
isms. Daptomycin has been used in the USA and Europe for
the treatment of complicated skin and soft tissue (cSSTI)
